Issues
-
Cover Image
Cover Image
Pelvic lymph nodes are the most frequent sites of prostate cancer dissemination, as depicted here by pan-cytokeratin immunohistochemistry on a human specimen. However, there is little knowledge about how precociously disseminated cancer cells seed lymph nodes and protect themselves from immune surveillance. Jachetti and colleagues report that early-disseminating cancer stem-like cells seed quiescent future sites of metastasis in tumor-draining lymph nodes by engaging Tenascin-C, a protumorigenic extracellular matrix protein, which mediates local immune escape by arresting T lymphocyte activation. For details, see article by Jachetti and colleagues on page 2095. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Breaking Advances
Reviews
Priority Reports
PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration-Resistant Prostate Cancer, Is a Mediator of Resistance to Androgen Deprivation Therapy
Integrated Systems and Technologies
Microenvironment and Immunology
Molecular and Cellular Pathobiology
The Endogenous Cell-Fate Factor Dachshund Restrains Prostate Epithelial Cell Migration via Repression of Cytokine Secretion via a CXCL Signaling Module
Therapeutics, Targets, and Chemical Biology
CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110
Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide
Nitrostyrene Derivatives Act as RXRα Ligands to Inhibit TNFα Activation of NF-κB
Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors
Tumor and Stem Cell Biology
MMP16 Mediates a Proteolytic Switch to Promote Cell–Cell Adhesion, Collagen Alignment, and Lymphatic Invasion in Melanoma
Tenascin-C Protects Cancer Stem–like Cells from Immune Surveillance by Arresting T-cell Activation
Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms
Chronic Inflammation Induces a Novel Epigenetic Program That Is Conserved in Intestinal Adenomas and in Colorectal Cancer
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.